Phentermine hydrochloride (HCI) is a sympathomimetic amine widely prescribed as a short-term pharmacological agent for obesity management. It primarily functions as an appetite suppressant by increasing norepinephrine release in the hypothalamus, thereby reducing hunger and food intake. Clinically, phentermine is indicated in patients with a body mass index (BMI) ≥30 kg/m3, or ≥27 kg/m2 with obesity-related comorbidities such as hypertension, type 2 diabetes, or dyslipidemia. Research evidence has consistently demonstrated that phentermine, when combined with dietary and lifestyle interventions, results in greater weight reduction compared to lifestyle interventions alone.

Adverse effects of phentermine are directly related to its sympathomimetic activity. Frequently reported reactions include elevated blood pressure, headache, tremor, insomnia, palpitations, overstimulation, dizziness, irritability, and dry mouth. These side effects vary in severity and warrant careful monitoring, especially in patients with underlying cardiovascular or neurological conditions. Rare but serious complications may include arrhythmias, psychiatric disturbances, and severe hypertensive episodes.

Clinical use of phentermine carries important warnings. It should be avoided in patients with uncontrolled hypertension, seizure disorders, and overactive thyroid (hyperthyroidism). Special caution is advised in individuals with psychiatric disorders, sleep disturbances, or a predisposition to stimulant misuse. Co-administration with other weight-loss agents is not recommended unless used in FDA-approved combination formulations such as phentermine/topiramate extended-release.

Contraindications are well established in research and clinical guidelines. Phentermine must not be used in patients with cardiovascular disease, including uncontrolled hypertension, coronary artery disease, arrhythmias, and stroke. It is contraindicated in glaucoma and in individuals with a history of drug or alcohol misuse due to its stimulant nature and potential for abuse. Additionally, it is unsafe to administer phentermine within 14 days of monoamine oxidase inhibitor (MAOI) therapy because of the risk of hypertensive crisis.

Research regarding long-term use of phentermine remains ongoing. Although traditionally limited to 12 weeks of treatment, observational studies suggest extended use may be both effective and safe in carefully monitored patients. However, due to the limited availability of large-scale randomized controlled trials on prolonged use, regulatory guidelines remain conservative, emphasizing short-term treatment under medical supervision.

In summary, phentermine is an effective short-term treatment for obesity that offers clinically significant weight reduction when combined with lifestyle modifications. Despite its benefits, it poses cardiovascular, neurological, and psychiatric risks that require vigilant monitoring. Contraindications must be strictly observed to ensure patient safety, and while emerging research suggests potential for longer-term use, its role in chronic obesity management remains carefully restricted within clinical practice.